Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Implications of targeted cancer therapies for elderly patients

SIOG 2014

23 - 25 Oct 2014

Published: 7 Nov 2014

Views: 2976

Rating:

Save

Prof Vesa Kataja - Kuopio University Hospital, Kuopio, Finland

At SIOG 2014, Prof Kataja speaks to ecancertv about the challenges of using new cancer therapeutics on the elderly population.

The latest therapeutics, such as targeted therapies, are rarely trialled on the elderly - what implications does this have for treatment?

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine...

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in...

Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )

2 year recurrence free survival benefit for resectable melanoma treated with...

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly...

Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain

$Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )$

More from ecancer